
- Oncology NEWS International Vol 16 No 6
- Volume 16
- Issue 6
Enrollment Begins for Phase I Trial of NPI-0052 in Myeloma
NORWALK, Connecticut—The Multiple Myeloma Research Consortium (MMRC) and Nereus Pharmaceuticals, Inc., San Diego, have initiated enrollment in a multicenter phase I clinical trial to study Nereus' novel, second-generation proteasome inhibitor NPI-0052 in patients with relapsed or relapsed/refractory multiple myeloma. Participants in the open-label study will receive escalating, once-weekly intravenous doses of NPI-0052. The compound was discovered during the fermentation of a new marine actinomycete (Salinispora tropica).
NORWALK, ConnecticutThe Multiple Myeloma Research Consortium (MMRC) and Nereus Pharmaceuticals, Inc., San Diego, have initiated enrollment in a multicenter phase I clinical trial to study Nereus' novel, second-generation proteasome inhibitor NPI-0052 in patients with relapsed or relapsed/refractory multiple myeloma. Participants in the open-label study will receive escalating, once-weekly intravenous doses of NPI-0052. The compound was discovered during the fermentation of a new marine actinomycete (Salinispora tropica).
Articles in this issue
over 18 years ago
ACS Launches Major Epidemiology Studyover 18 years ago
Pt Selection Key to Radioembolization of Liver Ca'sover 18 years ago
Million Dollar Gotham Prize Announcedover 18 years ago
Diagnostic Dilemma: GI Diseaseover 18 years ago
Junovan Fails to Win ODAC Nod for Osteosarcoma Treatmentover 18 years ago
Surveillance Colonoscopy Guidelines Not Being Followedover 18 years ago
Removing Stage IV Primary May Cut Mortalityover 18 years ago
Nuclear Export Inhibitors Testing Moving Forwardover 18 years ago
ODAC: orBec Yields No 'Substantial Efficacy' in GI GVHDNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.


















































































